ObjEcTIvE: Mitotane is an adrenocytolytic agent used in adrenocortical carcinoma, inducing adrenal insufficiency, requiring replacement treatment. Such therapy is not easy to monitor because of mitotane interference. Salivary cortisol reflects a free fraction of plasma cortisol and may be useful in such patients. DESIGN: The aim of our study was to evaluate salivary cortisol by HPlc coupled to tandem-mass spectrometry (lc-MS/MS) and by an electrochemiluminescence immunoassay (EclIA) in patients treated with mitotane. We enrolled 6 patients receiving mitotane and 2 Addison disease patients as negative controls and determined salivary cortisol rhythm. We also determined the salivary cortisol rhythm in 8 healthy subjects. Salivary samples (n=112) were assayed by EclIA, using roche Modular E170, and by lc-MS/MS. rESulTS: The mean values obtained by EclIA were significantly higher than those obtained by lc-MS/MS in the mitotane group (p<0.001). In fact, in the group measured by lc-MS/ MS, we observed several peaks eluting at a retention time different from the cortisol group, presumably due to cortisol-like analogues. In Addison disease, since steroidogenesis is absent, salivary cortisol values measured by the two methods did not show any significant difference (p=0.61). cONcluSIONS: Salivary cortisol measured by lc-MS/MS is a selective method, excluding cortisol analogues accumulating in treated patients. Therefore, lc-MS/MS offers an effective system to monitor replacement therapy in mitotane treated patients.